Related Experiment Videos
MUC1-specific anti-tumor responses: molecular requirements for CD4-mediated responses
Michelle L VanLith1, Karl G Kohlgraf, Connie L Sivinski
1Eppley Institute for Research in Cancer and Allied Diseases, and Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Abstract:
MUC1 was first defined as a tumor antigen in the late 1980s, yet little is known about the types of immune responses that mediate rejection of MUC1(+) tumors in vivo. MUC1-specific antibodies, T(h) cells and cytotoxic T cells can be detected in patients with different adenocarcinomas, yet these tumors usually progress. Thus, there is a need to better understand the in vivo mechanisms of antigen-specific tumor rejection. To characterize the nature of MUC1-specific immune responses in vivo, rejection of a MUC1-expressing melanoma tumor line (B16.MUC1) was evaluated in mice lacking specific T cell subsets, cytokines, co-stimulatory molecules or molecular effectors of cytolytic pathways. Results demonstrated that rejection of the B16.MUC1 tumor cell line was primarily mediated by CD4(+) T cells, and required Fas ligand, lymphotoxin-alpha, CD40, CD40 ligand and CD28, but not perforin, gammadelta T cells, IL-4, IL-10, IL-12 or tumor necrosis factor receptor-1. Depletion of NK cells demonstrated that NK cells might also contribute to MUC1 immunity in the B16.MUC1 tumor model. These results demonstrated that the immune response generated against MUC1 does not fit the type 1 or 2 model described for many immune responses. Additionally, multiple cytolytic mechanisms are required for B16.MUC1 rejection.
Insights
Tumor rejection of MUC1-expressing melanoma relies on CD4(+) T cells and specific molecular pathways, not typical Type 1 or Type 2 immune responses. Understanding these mechanisms is crucial for developing effective cancer immunotherapies.
Area of Science:
- Immunology
- Cancer Biology
- Tumor Immunology
Background:
- MUC1 is a known tumor antigen, but the immune mechanisms for rejecting MUC1(+) tumors in vivo remain unclear.
- Despite detectable MUC1-specific immune cells in cancer patients, tumors often progress, highlighting a gap in understanding tumor rejection.
Purpose of the Study:
- To elucidate the in vivo immune response mechanisms responsible for rejecting MUC1-expressing tumors.
- To characterize the specific immune cells, cytokines, and molecular pathways involved in MUC1 tumor rejection.
Main Methods:
- Utilized a MUC1-expressing melanoma mouse model (B16.MUC1).
- Evaluated tumor rejection in mice with deficiencies in T cell subsets, cytokines, co-stimulatory molecules, and cytolytic pathway effectors.
- Assessed the role of NK cells in MUC1 immunity.
Main Results:
- Rejection of B16.MUC1 tumors was primarily mediated by CD4(+) T cells.
- Key requirements for rejection included Fas ligand, lymphotoxin-alpha, CD40, CD40 ligand, and CD28.
- Perforin, gammadelta T cells, IL-4, IL-10, IL-12, and TNF-R1 were not essential for rejection.
- NK cells may also contribute to MUC1 immunity.
- The immune response did not align with traditional Type 1 or Type 2 models.
Conclusions:
- MUC1 tumor rejection involves a complex interplay of CD4(+) T cells and specific co-stimulatory/cytolytic pathways.
- The immune response against MUC1 is distinct from established Type 1/Type 2 paradigms.
- Multiple cytolytic mechanisms are necessary for effective MUC1-expressing tumor rejection.